临床荟萃
臨床薈萃
림상회췌
CLINICAL FOCUS
2014年
5期
512-514
,共3页
扈艳婷%王旭%马克威%李薇
扈豔婷%王旭%馬剋威%李薇
호염정%왕욱%마극위%리미
小细胞肺癌%ADH 分泌不当综合征%低钠血症
小細胞肺癌%ADH 分泌不噹綜閤徵%低鈉血癥
소세포폐암%ADH 분비불당종합정%저납혈증
small cell lung carcinoma%inappropriate ADH syndrome%hyponatremia
目的：探讨合并抗利尿激素分泌不当综合征(SIADH)的局限期小细胞肺癌(SCLC)患者的临床特点及预后情况。方法回顾性分析经吉林大学第一医院确诊的63例局限期 SCLC 患者,比较正常血钠组患者及合并SIADH 组患者无进展生存期(PFS)、总生存期(OS)、1年生存率、2年及3年生存率的异同。结果局限期 SCLC 合并SIADH 的发生率为12.7%(8/63),SIADH 组与正常血钠组 PFS 分别为(239.4±143.9)天 vs (403.4±166.7)天(P <0.05)；两组 OS 分别为(337.8±237.7)天 vs (683.8±343.3)天(P <0.05),差异有统计学意义；两组1年生存率为37.5%(3/8)vs 85.5%(47/55),P <0.05,差异有统计学意义；2年及3年生存率分别为12.5%(1/8)vs 47.3%(26/55)、0 vs 25.5%(14/55)(P >0.05),差异无统计学意义。结论局限期 SCLC 合并 SIADH 的发生率并不低,并发SIADH 的局限期 SCLC 预后更差,临床上应高度警惕局限期 SCLC 合并 SIADH 并及时治疗。
目的：探討閤併抗利尿激素分泌不噹綜閤徵(SIADH)的跼限期小細胞肺癌(SCLC)患者的臨床特點及預後情況。方法迴顧性分析經吉林大學第一醫院確診的63例跼限期 SCLC 患者,比較正常血鈉組患者及閤併SIADH 組患者無進展生存期(PFS)、總生存期(OS)、1年生存率、2年及3年生存率的異同。結果跼限期 SCLC 閤併SIADH 的髮生率為12.7%(8/63),SIADH 組與正常血鈉組 PFS 分彆為(239.4±143.9)天 vs (403.4±166.7)天(P <0.05)；兩組 OS 分彆為(337.8±237.7)天 vs (683.8±343.3)天(P <0.05),差異有統計學意義；兩組1年生存率為37.5%(3/8)vs 85.5%(47/55),P <0.05,差異有統計學意義；2年及3年生存率分彆為12.5%(1/8)vs 47.3%(26/55)、0 vs 25.5%(14/55)(P >0.05),差異無統計學意義。結論跼限期 SCLC 閤併 SIADH 的髮生率併不低,併髮SIADH 的跼限期 SCLC 預後更差,臨床上應高度警惕跼限期 SCLC 閤併 SIADH 併及時治療。
목적：탐토합병항이뇨격소분비불당종합정(SIADH)적국한기소세포폐암(SCLC)환자적림상특점급예후정황。방법회고성분석경길림대학제일의원학진적63례국한기 SCLC 환자,비교정상혈납조환자급합병SIADH 조환자무진전생존기(PFS)、총생존기(OS)、1년생존솔、2년급3년생존솔적이동。결과국한기 SCLC 합병SIADH 적발생솔위12.7%(8/63),SIADH 조여정상혈납조 PFS 분별위(239.4±143.9)천 vs (403.4±166.7)천(P <0.05)；량조 OS 분별위(337.8±237.7)천 vs (683.8±343.3)천(P <0.05),차이유통계학의의；량조1년생존솔위37.5%(3/8)vs 85.5%(47/55),P <0.05,차이유통계학의의；2년급3년생존솔분별위12.5%(1/8)vs 47.3%(26/55)、0 vs 25.5%(14/55)(P >0.05),차이무통계학의의。결론국한기 SCLC 합병 SIADH 적발생솔병불저,병발SIADH 적국한기 SCLC 예후경차,림상상응고도경척국한기 SCLC 합병 SIADH 병급시치료。
Objective To investigate the clinical characteristics and prognostic value of limited small cell lung cancer(SCLC)with inappropriate antidiuretic hormone secretion(SIADH).Methods We retrospectively reviewed 63 limited SCLC patients who were diagnosed limited SCLC at the First Hospital of Jilin University.Comparison was made in progression-free-survival(PFS),overall-survival(OS),one-year survival rate,two and three-year survival rate between limited SCLC without SIADH group and limited SCLC with SIADH group.Results 12.7% cases (8/63)of limited SCLC patients possessed SIADH complication.The PFS was (403.4±1 66.7)days and (239.4±143.9)days in limited SCLC without SIADH group and limited SCLC with SIADH group,respectively (P <0.05);OS was (683.8± 343.3)days and (337.8±237.7)days,respectively(P <0.05 );both PFS and OS of limited SCLC without SIADH group were significantly longer than those of patients of limited SCLC with SIADH group.One-year survival rate of limited SCLC without SIADH group and limited SCLC with SIADH group was 37.5% (3/8)and 85.5% (47/55 ), respectively (P <0.05);two-year survival rate was 12.5%(1/8)and 47.3%(26/55 ),three-year survival rate was 0 and 25.5% (14/55 ),respectively (P > 0.05 ).Conclusion The incidence of SIADH was high in SCLC patients. Compared with limited SCLC without SIADH patients,the prognosis of limited SCLC with SIADH patients was poor. More attention is paid to SIADH in limited SCLC and timely treatment should be provided.
